Javascript must be enabled to continue!
Serum symmetric dimethylarginine concentrations in enalapril- or telmisartan-treated dogs with proteinuric chronic kidney disease
View through CrossRef
IntroductionRenin-angiotensin-aldosterone system inhibition (RAASi) reduces intraglomerular pressure and is a standard therapy for dogs with proteinuric chronic kidney disease (CKD). RAASi can acutely decrease glomerular filtration rate (GFR); however, its effects on the marker of GFR serum symmetric dimethylarginine (SDMA) concentration in dogs have not been specifically evaluated. The objective of this study was to evaluate changes, relative to pretreatment values, in serum SDMA concentrations in dogs with proteinuric CKD receiving RAASi therapy.MethodsThis retrospective study used banked samples from 29 dogs with proteinuric CKD treated with enalapril (0.5 mg/kg PO q12h; n = 16) or telmisartan (1 mg/kg PO q24h; n = 13) alone (n = 22) or in combination with amlodipine if severely hypertensive (n = 7). Serum SDMA, creatinine, and urea nitrogen (SUN) concentrations were measured before and 7 and 30 days after starting RAASi. Percentage and absolute changes in these biomarkers were calculated for each dog and time point. A linear mixed model was used to test whether changes significantly differed from zero (α < 0.05).ResultsOverall, mean ± SEM Day 7 and 30 percentage change in SDMA were − 4.8 ± 3.6% and − 3.2 ± 3.4%, respectively; in creatinine were 7.4 ± 3.3% and 3.0 ± 3.1%, respectively; and in SUN were 22.1 ± 6.8% and 16.7 ± 6.2%, respectively. Mean changes varied according to whether all dogs, those on RAASi alone, or those co-treated with amlodipine were evaluated. In dogs receiving RAASi alone, at day 7, there were significant mean percentual increases in creatinine (9%; p = 0.023) and SUN (23%; p = 0.005), but SDMA was unchanged. In dogs co-treated with amlodipine, a significant absolute decrease in mean SDMA (−2.29 μg/dL; p = 0.026) occurred at days 7 and 30, while mean creatinine was unchanged and mean SUN increased.DiscussionProteinuric dogs receiving RAASi had low-magnitude changes in serum SDMA and creatinine, and moderate-magnitude changes in SUN concentrations. The direction of change in SDMA did not consistently match that of creatinine and SUN.
Title: Serum symmetric dimethylarginine concentrations in enalapril- or telmisartan-treated dogs with proteinuric chronic kidney disease
Description:
IntroductionRenin-angiotensin-aldosterone system inhibition (RAASi) reduces intraglomerular pressure and is a standard therapy for dogs with proteinuric chronic kidney disease (CKD).
RAASi can acutely decrease glomerular filtration rate (GFR); however, its effects on the marker of GFR serum symmetric dimethylarginine (SDMA) concentration in dogs have not been specifically evaluated.
The objective of this study was to evaluate changes, relative to pretreatment values, in serum SDMA concentrations in dogs with proteinuric CKD receiving RAASi therapy.
MethodsThis retrospective study used banked samples from 29 dogs with proteinuric CKD treated with enalapril (0.
5 mg/kg PO q12h; n = 16) or telmisartan (1 mg/kg PO q24h; n = 13) alone (n = 22) or in combination with amlodipine if severely hypertensive (n = 7).
Serum SDMA, creatinine, and urea nitrogen (SUN) concentrations were measured before and 7 and 30 days after starting RAASi.
Percentage and absolute changes in these biomarkers were calculated for each dog and time point.
A linear mixed model was used to test whether changes significantly differed from zero (α < 0.
05).
ResultsOverall, mean ± SEM Day 7 and 30 percentage change in SDMA were − 4.
8 ± 3.
6% and − 3.
2 ± 3.
4%, respectively; in creatinine were 7.
4 ± 3.
3% and 3.
0 ± 3.
1%, respectively; and in SUN were 22.
1 ± 6.
8% and 16.
7 ± 6.
2%, respectively.
Mean changes varied according to whether all dogs, those on RAASi alone, or those co-treated with amlodipine were evaluated.
In dogs receiving RAASi alone, at day 7, there were significant mean percentual increases in creatinine (9%; p = 0.
023) and SUN (23%; p = 0.
005), but SDMA was unchanged.
In dogs co-treated with amlodipine, a significant absolute decrease in mean SDMA (−2.
29 μg/dL; p = 0.
026) occurred at days 7 and 30, while mean creatinine was unchanged and mean SUN increased.
DiscussionProteinuric dogs receiving RAASi had low-magnitude changes in serum SDMA and creatinine, and moderate-magnitude changes in SUN concentrations.
The direction of change in SDMA did not consistently match that of creatinine and SUN.
Related Results
Hemodynamic and clinical effects of enalapril in management of children with congestive heart failure : a randomized, placebo-controlled study
Hemodynamic and clinical effects of enalapril in management of children with congestive heart failure : a randomized, placebo-controlled study
Objective: To assess hemodynamic and clinical effects of Enalapril in treating children with congestive heart failure and possible side effects of Enalapril in pediatric population...
MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells
MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells
Background:
Pancreatic ductal adenocarcinoma (PDAC) is the most devastating of all cancers with an extremely poor prognosis. It has few effective and reliable therapeut...
Comparative Study of Olmesartan versus Telmisartan, in Patient with Stage I Hypertension
Comparative Study of Olmesartan versus Telmisartan, in Patient with Stage I Hypertension
Background: Hypertension is one of the most common diseases in the world. It is defined as sustained increase in blood pressure ≥ 140/90 mmHg. The risk of both microvascular & ...
e0188 Enalapril, Irbesartan and Ang-(1-7) prevent atrial tachycardia-induced sodium channel remodelling
e0188 Enalapril, Irbesartan and Ang-(1-7) prevent atrial tachycardia-induced sodium channel remodelling
Purpose
Recent studies indicated that the activation of renin-angiotensin system (RAS) played an important role in the development and recurrence of atrial fibril...
Serum and Fecal 3-Bromotyrosine Concentrations in Dogs with Chronic Inflammatory Enteropathy: Clinical Parameters and Histopathological Changes
Serum and Fecal 3-Bromotyrosine Concentrations in Dogs with Chronic Inflammatory Enteropathy: Clinical Parameters and Histopathological Changes
Chronic inflammatory enteropathies (CIEs) in dogs involve the infiltration of gastrointestinal tissue with inflammatory cells. This study aimed to assess the sensitivity of serum a...
COMPARATIVE STUDY ON THE BENEFICIAL EFFECTS OF TELMISARTAN AND OTHER ANTIHYPERTENSIVE AGENTS IN STROKE PATIENTS
COMPARATIVE STUDY ON THE BENEFICIAL EFFECTS OF TELMISARTAN AND OTHER ANTIHYPERTENSIVE AGENTS IN STROKE PATIENTS
<p class="ParaAttribute0">Objective<strong>:</strong> To compare the beneficial effects of telmisartan with other anti-hypertensive agents during stroke with resp...
Effects of telmisartan on lipid metabolisms and proinflammatory factors secretion of differentiated 3T3-L1 adipocytes
Effects of telmisartan on lipid metabolisms and proinflammatory factors secretion of differentiated 3T3-L1 adipocytes
Aim: To investigate the effect of telmisartan on the lipometabolisms and the proinflammatory factors secreted from 3T3-L1 adipocytes and to explore the possible mechanisms. Materia...
Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension.
Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension.
We have recently shown that treatment with the calcium channel blocker nitrendipine may aggravate albuminuria and glomerular injury in rats with two-kidney, one clip renovascular h...

